Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC
Status:
Completed
Trial end date:
2018-12-07
Target enrollment:
Participant gender:
Summary
This is a single arm, open label, Phase II study in KRAS-positive and KRAS-negative patients
with stage IV (including pleural effusion) non squamous NSCLC who have failed two lines of
anti-cancer therapy. A maximum of 60 evaluable patients with NSCLC will receive
antroquinonol, of which 30 patients will be KRAS-positive and 30 patients KRAS-negative. An
evaluable patient will have received at least one dose of antroquinonol and have a valid
baseline tumor assessment. Enrollment will continue until the target number of evaluable
patients has been enrolled.